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background
 
Current guidelines recommend an early invasive strategy for patients who have acute
coronary syndromes without ST-segment elevation and with an elevated cardiac tropo-
nin T level. However, randomized trials have not shown an overall reduction in mortal-
ity, and the reduction in the rate of myocardial infarction in previous trials has varied
depending on the definition of myocardial infarction.
 
methods
 
We randomly assigned 1200 patients with acute coronary syndrome without ST-seg-
ment elevation who had chest pain, an elevated cardiac troponin T level (≥0.03 
 
µ
 
g per
liter), and either electrocardiographic evidence of ischemia at admission or a docu-
mented history of coronary disease to an early invasive strategy or to a more conser-
vative (selectively invasive) strategy. Patients received aspirin daily, enoxaparin for 48
hours, and abciximab at the time of percutaneous coronary intervention. The use of
clopidogrel and intensive lipid-lowering therapy was recommended. The primary end
point was a composite of death, nonfatal myocardial infarction, or rehospitalization
for anginal symptoms within one year after randomization.
 
results
 
The estimated cumulative rate of the primary end point was 22.7 percent in the group
assigned to early invasive management and 21.2 percent in the group assigned to se-
lectively invasive management (relative risk, 1.07; 95 percent confidence interval, 0.87
to 1.33; P=0.33). The mortality rate was the same in the two groups (2.5 percent).
Myocardial infarction was significantly more frequent in the group assigned to early
invasive management (15.0 percent vs. 10.0 percent, P=0.005), but rehospitalization
was less frequent in that group (7.4 percent vs. 10.9 percent, P=0.04).
 
conclusions
 
We could not demonstrate that, given optimized medical therapy, an early invasive strat-
egy was superior to a selectively invasive strategy in patients with acute coronary syn-
dromes without ST-segment elevation and with an elevated cardiac troponin T level.
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atients with acute coronary
 
 
 
syn
 
-
dromes without ST-segment elevation are
at risk for adverse cardiac events.
 
1
 
 Optimal
treatment consists of intensive medical therapy
followed by diagnostic coronary angiography and
revascularization in some patients. In five large, ran-
domized trials (Veterans Affairs Non–Q-Wave In-
farction Strategies in Hospital [VANQWISH], Frag-
min and Fast Revascularization during Instability
in Coronary Artery Disease [FRISC] II, Treat Angi-
na with Aggrastat and Determine Cost of Therapy
with an Invasive or Conservative Strategy–Throm-
bolysis in Myocardial Infarction 18 [TACTICS–
TIMI 18], TIMI IIIB, and the Third Randomized
Intervention Treatment of Angina [RITA-3]), a rou-
tine, early invasive strategy (early angiography
followed by revascularization, depending on an-
giographic findings) was compared with a “con-
servative” strategy (angiography and subsequent
revascularization only if medical therapy failed or
substantial residual ischemia was documented).
 
2-6
 
An early invasive strategy was shown to be beneficial
in the FRISC II, TACTICS–TIMI 18, and RITA-3 stud-
ies, especially in subgroups of patients at high
risk, such as those presenting with an elevated car-
diac troponin level. As a result, recent guidelines
of the American College of Cardiology–American
Heart Association and the European Society of
Cardiology recommend an early invasive approach
in high-risk patients with acute coronary syndromes
without ST-segment elevation.
 
7,8
 
Despite these recommendations, it is not clear
that an early invasive strategy reduces mortality in
this setting. A reduction in mortality was shown in
the FRISC II study, but only among men. Such a re-
duction was not seen in any of the other studies. In
addition, the reduction in the incidence of myo-
cardial infarction associated with an early invasive
strategy in these studies depended on the defini-
tion of myocardial infarction. Moreover, recent ad-
vances in medical therapy, such as the early use of
clopidogrel and intensive lipid-lowering therapy,
have been shown to improve the prognosis in pa-
tients with acute coronary syndromes.
 
9,10
 
 These
therapies have not been tested in trials of early inva-
sive strategies. Therefore, we conducted the present
study to test the hypothesis that an early invasive
strategy is superior to a selectively invasive strategy
for patients who have acute coronary syndromes
without ST-segment elevation and with an elevated
cardiac troponin T level.
 
study population and study design
 
Between July 2001 and August 2003, 1200 patients
were enrolled from 42 Dutch hospitals, 12 of
which were high-volume centers with facilities for
percutaneous coronary intervention and on-site
cardiac surgery. The protocol was approved by all
the local institutional review boards. All patients
gave written informed consent. The trial was fund-
ed by a combination of sources. The sponsors had
no involvement in the design of the study, data col-
lection or analysis, or the writing of the manu-
script.
Eligible patients had to have all three of the fol-
lowing: symptoms of ischemia that were increas-
ing or occurred at rest, with the last episode occur-
ring no more than 24 hours before randomization;
an elevated cardiac troponin T level (≥0.03 
 
µ
 
g per
liter); and either ischemic changes as assessed by
electrocardiography (defined as ST-segment de-
pression or transient ST-segment elevation exceed-
ing 0.05 mV, or T-wave inversion of ≥0.2 mV in two
contiguous leads) or a documented history of coro-
nary artery disease as evidenced by previous myo-
cardial infarction, findings on previous coronary
angiography, or a positive exercise test. Exclusion
criteria were an age younger than 18 years or older
than 80 years, myocardial infarction with ST-seg-
ment elevation in the past 48 hours, an indication
for primary percutaneous coronary intervention
or fibrinolytic therapy, hemodynamic instability
or overt congestive heart failure, the use of oral
anticoagulant drugs in the past 7 days, fibrinolyt-
ic treatment within the past 96 hours, percutane-
ous coronary intervention within the past 14 days,
a contraindication to treatment with percutaneous
coronary intervention or glycoprotein IIb/IIIa in-
hibitors, recent trauma or risk of bleeding, hyper-
tension despite treatment (i.e., systolic pressure
>180 mm Hg or diastolic pressure >100 mm Hg),
weight greater than 120 kg, or inability to give in-
formed consent.
 
optimized medical therapy
 
The protocol specified that patients receive 300 mg
of aspirin at the time of randomization, followed
by at least 75 mg daily indefinitely, and enoxaparin
(1 mg per kilogram of body weight, to a maximum
of 80 mg) twice daily subcutaneously for at least
48 hours. Patients already started on unfraction-
p methods
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on May 8, 2012. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;11
 
www.nejm.org september 
 
15, 2005
 
invasive vs. conservative management for acute coronary syndromes
 
1097
 
ated heparin were switched to enoxaparin imme-
diately after randomization. The early use of clo-
pidogrel (300 mg immediately, followed by 75 mg
daily) in combination with aspirin was recom-
mended to the investigators after the drug was ap-
proved in 2002 for the indication of acute coronary
syndromes.
 
9
 
 
All interventional procedures during the initial
hospital phase were performed with the use of ab-
ciximab, given as a bolus dose of 0.25 mg per ki-
logram, followed by an infusion of 0.125 
 
µ
 
g per
kilogram per minute for 12 hours, and started 10
to 60 minutes before the first balloon inflation.
 
11
 
Abciximab was also available for use in patients
who subsequently underwent percutaneous revas-
cularization. The protocol recommended inten-
sive lipid-lowering therapy, preferably 80 mg of
atorvastatin daily or the equivalent, started as soon
as possible after randomization and continued in-
definitely. The level of the MB isoform of creatine
kinase (CK-MB) was measured at 6-hour intervals
during the first period of 24 hours or more after ad-
mission, after each new clinical episode of ische-
mia, and after each percutaneous revasculariza-
tion procedure.
 
treatment strategy
 
Patients were randomly assigned to an early inva-
sive strategy or a selectively invasive strategy with
the use of a central telephone system. Permuted-
block randomization was performed, with stratifi-
cation according to site, with block size randomly
chosen to be four, six, or eight. Patients assigned to
the early invasive strategy were scheduled to under-
go angiography within 24 to 48 hours after ran-
domization and percutaneous coronary interven-
tion when appropriate on the basis of the coronary
anatomy. Coronary-artery bypass grafting was rec-
ommended in patients with extensive three-vessel
disease or severe left main-stem disease and was to
be performed as soon as possible during the initial
hospitalization period. 
Patients assigned to the selectively invasive strat-
egy were treated medically. These patients were
scheduled to undergo angiography and subsequent
revascularization only if they had refractory angina
despite optimal medical treatment, hemodynamic
or rhythmic instability, or clinically significant is-
chemia on the predischarge exercise test. Coronary
angiography and revascularization after the initial
hospital phase were performed if severe anginal
symptoms (i.e., Canadian Cardiovascular Society
[CCS] class III or IV) persisted despite optimal
antianginal medication or if ischemia was docu-
mented on subsequent testing. Follow-up outpa-
tient visits occurred at 1, 6, and 12 months after ran-
domization.
 
end points
 
The primary end point was a composite of death,
recurrent myocardial infarction, or rehospitaliza-
tion for angina within one year after randomiza-
tion. Death was defined as death from any cause.
Myocardial infarction was defined as documented
myocardial necrosis, occurring either spontane-
ously or in the setting of percutaneous interven-
tion, according to the recommendations of the Joint
European Society of Cardiology–American College
of Cardiology Committee for the Redefinition of
Myocardial Infarction.
 
12
 
 Myocardial necrosis was
defined by an elevation in the CK-MB level above
the upper limit of normal. In the event of an ele-
vated CK-MB level at randomization, recurrent
myocardial infarction during the first 48 hours was
diagnosed when there was a 50 percent decrease
from a previous peak value, followed by a subse-
quent rise to a level exceeding the upper limit of
normal. A myocardial infarction in the setting of
coronary-artery bypass grafting required the oc-
currence of electrocardiographic evidence of new
Q waves. 
Major bleeding not related to coronary-artery
bypass grafting during the index admission was
defined by at least one of the following: fatal bleed-
ing, intracranial bleeding, a need for blood trans-
fusion, a decrease of 3 mmol per liter (4.8 g per deci-
liter) or more in hemoglobin levels, and bleeding
resulting in hemodynamic compromise. All end
points were adjudicated by members of an inde-
pendent clinical end-points committee, who were
unaware of the treatment assignments of the pa-
tients.
 
statistical analysis
 
We calculated that, given a 21 percent incidence
of the primary end point in the group assigned to
an early invasive strategy, 1200 patients would be
needed to provide the study with 80 percent power
to detect a relative risk reduction of 25 percent be-
tween the two groups, at an alpha level of 0.05.
Continuous variables with normal distributions are
expressed as means ±SD and were compared with
the use of an unpaired Student’s t-test. Categorical
variables were compared with the use of Fisher’s
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exact test or the chi-square test, where appropriate.
All reported P values are two-sided and not adjust-
ed for multiple testing.
Event rates at one year were estimated with the
Kaplan–Meier method.
 
13
 
 Relative risks were cal-
culated by dividing the Kaplan–Meier estimated
rate of an event at one year in the early-invasive-
strategy group by that in the group assigned to a se-
lectively invasive strategy. The 95 percent confi-
dence interval for the relative risk was calculated
with the use of the standard errors from the Kaplan–
Meier curve. The significance of differences in event
rates between treatment groups was assessed with
the use of the log-rank test. Data on patients who
were lost to follow-up were censored at the time of
the last contact.
A total of 604 patients were randomly assigned
to the early invasive strategy and 596 patients to
the selectively invasive strategy. Baseline charac-
teristics are shown in Table 1. The median age
was 62 years, about three quarters of the patients
were male, and 14 percent had diabetes. Cardiac
catheterization was performed during the initial
hospitalization in 98 percent of patients in the early-
invasive-strategy group and 53 percent in the se-
lectively-invasive-strategy group, and in 99 percent
and 67 percent, respectively, within one year (Ta-
ble 2). Within one year, 79 percent of the patients
in the early-invasive-strategy group had undergone
revascularization, as compared with 54 percent in
the selectively-invasive-strategy group. Eighty-eight
percent of the percutaneous coronary intervention
procedures in both treatment groups combined
involved the placement of at least one stent. Med-
ical therapy at discharge was similar between the
group assigned to an early invasive strategy and the
group assigned to a selectively invasive strategy,
except for the use of clopidogrel (61 percent vs. 49
percent, respectively). The incidence of statin use
at discharge was very high in both groups (90 per-
cent and 94 percent, respectively).
 
primary end point
 
Six patients were lost to follow-up before one year.
A total of 263 patients (137 patients in the early-
invasive-strategy group and 126 patients in the
selectively-invasive-strategy group) reached the pri-
mary end point. Kaplan–Meier curves for the pri-
mary end point are shown in Figure 1. The estimat-
results
 
* Differences between the treatment groups were not statistically significant. 
Plus–minus values are means ±SD.
† Body-mass index is the weight in kilograms divided by the square of the height 
in meters.
‡ Cardiac troponin T levels were measured at the clinical chemistry core labora-
 
tory on the Elecsys 2010 system (Roche Diagnostics, Germany).
 
Table 1. Baseline Characteristics of the Patients.*
Characteristic 
Early 
Invasive 
Strategy 
(N=604)
Selectively 
Invasive 
Strategy 
(N=596)
 
Age — yr
Median 62 62
Range 29–81 30–83
Age ≥65 yr — no. (%) 263 (44) 266 (45)
Male sex — no. (%) 446 (74) 434 (73)
Body-mass index† 27±4 27±4
Clinical history — no. (%)
Myocardial infarction 153 (25) 125 (21)
Percutaneous coronary intervention 77 (13) 63 (11)
Coronary-artery bypass grafting 62 (10) 43 (7)
Risk factors — no. (%)
Hypertension 226 (37) 240 (40)
Diabetes mellitus 86 (14) 80 (13)
Hypercholesterolemia 211 (35) 206 (35)
Current cigarette smoking 244 (40) 248 (42)
Family history of coronary artery disease 263 (44) 241 (40)
Known left ventricular ejection fraction <35% 10 (2) 7 (1)
Medications at admission — no. (%)
Aspirin 235 (39) 221 (37)
Angiotensin-converting–enzyme inhibitors 88 (15) 82 (14)
Beta-blockers 220 (36) 196 (33)
Calcium-channel antagonists 92 (15) 96 (16)
Nitrates 70 (12) 64 (11)
Statins 172 (28) 157 (26)
Time from onset of symptoms 
to randomization — hr 
17±10 17±9
Electrocardiographic evidence of abnormalities 
at admission — no. (%)
ST-segment deviation ≥0.1 mV 284 (47) 290 (49)
Isolated T-wave inversion 48 (8) 44 (7)
Electrocardiogram missing or unreadable 26 (4) 25 (4)
Cardiac troponin T level‡
<0.10 
 
µ
 
g/liter 108 (18) 110 (18)
0.10–0.29 
 
µ
 
g/liter 199 (33) 195 (33)
0.30–0.99 
 
µ
 
g/liter 186 (31) 186 (31)
≥1.0 
 
µ
 
g/liter 111 (18) 105 (18)
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on May 8, 2012. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;11
 
www.nejm.org september 
 
15, 2005
 
invasive vs. conservative management for acute coronary syndromes
 
1099
 
ed one-year cumulative event rate was 22.7 percent
in the early-invasive-strategy group and 21.2 per-
cent in the group assigned to a selectively invasive
strategy (relative risk, 1.07; 95 percent confidence
interval, 0.87 to 1.33; P=0.33) (Table 3). One-year
mortality was 2.5 percent in both groups (relative
risk, 0.99; 95 percent confidence interval, 0.49 to
2.00; P=0.97). The cumulative risk of myocardial
infarction within one year after randomization was
significantly higher in the early-invasive-strategy
group (15.0 percent vs. 10.0 percent; relative risk,
1.50; 95 percent confidence interval, 1.10 to 2.04;
P=0.005). Rehospitalization was less frequent in
the early-invasive-strategy group (7.4 percent vs.
10.9 percent; relative risk, 0.68; 95 percent confi-
dence interval, 0.47 to 0.98; P=0.04).
Several baseline clinical features were examined
for potential effects in a subgroup analysis. The rel-
ative risks were not different among the major sub-
groups defined according to age, sex, the presence
or absence of diabetes mellitus, the presence or ab-
sence of ST-segment deviation, or the level of car-
diac troponin T (Fig. 2).
 
myocardial infarction
 
Categories of infarct size according to peak CK-MB
level are shown in Table 3. The rate of myocardial
infarction among patients with a peak CK-MB level
one to three times the upper limit of normal was
significantly higher in the early-invasive-strategy
group than in the group assigned to a selectively in-
vasive strategy (7.2 percent vs. 4.6 percent, P=0.05).
The incidence of myocardial infarction related to
percutaneous coronary intervention or coronary-
artery bypass grafting was also significantly higher
in the early-invasive-strategy group (11.3 percent
vs. 5.4 percent, P=0.001). To compare our results
with those of previous trials, we applied the defini-
tions of myocardial infarction from the FRISC II
 
4
 
and the TACTICS–TIMI 18
 
5
 
 studies to our data (Ta-
ble 3). Applying these definitions lowered the rate
of infarction. However, the relative risks remained
essentially unaltered, and there were no significant
differences in the rate of the composite primary end
point between the groups, irrespective of the defi-
nition of infarction applied.
 
other secondary end points
 
The percentage of patients free from anginal symp-
toms was similar in the early-invasive-strategy
group and the group assigned to a selectively inva-
sive strategy (86 percent and 87 percent, respec-
tively). Moreover, the incidence of angina, defined
as CCS class I to IV, was similar in the two groups
(data not shown). Major bleeding not related to
coronary-artery bypass grafting during the index
admission occurred in 19 patients (3.1 percent) in
the early-invasive-strategy group, as compared with
 
* The median time to percutaneous coronary intervention was 23 hours (25th to 75th percentile, 15 to 44) in the early-
invasive-strategy group and 283 hours (25th to 75th percentile, 142 to 647) in the group assigned to a selectively invasive 
strategy. During initial hospitalization, procedures involving percutaneous coronary intervention were performed, accompa-
nied by the use of abciximab, in 94 percent of patients undergoing percutaneous coronary intervention in the early-inva-
sive-strategy group and 75 percent of those undergoing percutaneous coronary intervention in the selectively-invasive-
strategy group. Within one year after randomization, 93 percent and 69 percent of procedures, respectively, involving 
 
percutaneous coronary intervention were performed, accompanied by the use of abciximab.
 
Table 2. Cardiac Procedures within Two Days after Randomization, during Initial Hospitalization, and within One Year, 
According to Study Group.
Procedure Within Two Days
During Initial 
Hospitalization Within One Year
 
Early 
Invasive 
Strategy
(N=604)
Selectively 
Invasive 
Strategy
(N=596)
Early 
Invasive 
Strategy
(N=604)
Selectively 
Invasive 
Strategy
(N=596)
Early 
Invasive 
Strategy
(N=604)
Selectively 
Invasive 
Strategy
(N=596)
 
number (percent)
 
Catheterization 588 (97) 64 (11) 593 (98) 314 (53) 597 (99) 397 (67)
Percutaneous coronary intervention* 321 (53) 22 (4) 361 (60) 169 (28) 371 (61) 239 (40)
Coronary-artery bypass grafting 15 (2) 1 (<1) 97 (16) 68 (11) 107 (18) 85 (14)
Revascularization 336 (56) 23 (4) 458 (76) 237 (40) 478 (79) 324 (54)
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10 patients (1.7 percent) in the group assigned to
a selectively invasive strategy.
This study did not show that an early invasive strat-
egy was superior to a selectively invasive strategy in
patients who had an acute coronary syndrome with-
out ST-segment elevation and who had an elevat-
ed cardiac troponin T level. Mortality within one
year was low (2.5 percent in both groups), despite
the fact that these patients were all considered at
high risk. The incidence of myocardial infarction
was significantly higher in the early-invasive-strat-
egy group, particularly during hospitalization, con-
firming the finding of the FRISC II researchers
 
4
 
that there is an early hazard associated with early
revascularization. The incidence of the primary
end point was 22.7 percent in the early-invasive-
strategy group, but 21.2 percent in the group as-
signed to a selectively invasive strategy, which was
lower than anticipated. There was no significant
difference in the frequency of the primary end
point among subgroups defined according to age,
sex, the presence or absence of diabetes mellitus,
the presence or absence of ST-segment deviation,
or the level of cardiac troponin T.
Comparing the results of the present study with
those of previous trials is not straightforward, ow-
ing to differences in study design, in the risk pro-
file of patients included, in antithrombotic thera-
py, and in the definition of end points, in particular
the definition of myocardial infarction; changes
in the practice of invasive therapy (especially the
use of stents and glycoprotein IIb/IIIa inhibitors);
and the observed contrast between strategies in the
rate and timing of revascularization. There are sev-
eral possible explanations for the observed differ-
ences in outcome between the present study and
previous trials.
First, revascularization rates were high in the
two groups in our study (76 percent in the early-
invasive-strategy group and 40 percent in the selec-
tively-invasive-strategy group during the initial
hospitalization, and 79 percent and 54 percent,
respectively, within 1 year after randomization) as
compared with those in TIMI-IIIb (64 percent vs.
58 percent at 1 year), VANQWISH (44 percent vs.
33 percent at 23 months), FRISC II (71 percent
vs. 9 percent at 10 days, and 77 percent vs. 37 per-
cent at 6 months), TACTICS–TIMI 18 (61 percent
vs. 44 percent at 6 months), and RITA-3 (44 percent
vs. 10 percent during the index admission, and 57
percent vs. 28 percent within 1 year).
 
14
 
 As in the
VANQWISH trial, all patients in our study had evi-
dence of myocardial necrosis, as compared with 58
percent with an elevated troponin level in FRISC II,
54 percent in TACTICS–TIMI 18, and 75 percent in
RITA-3. The fact that all patients in the present study
were at high risk (as evidenced by an elevated tro-
ponin level) may explain the earlier and more fre-
quent revascularization in the group assigned to a
selectively invasive strategy in our study. The 40
percent rate of revascularization during the initial
hospitalization in the group assigned to a selectively
invasive strategy in our study compares well with
the 48 percent rate of revascularization in patients
with acute coronary syndromes who were admitted
to centers with catheterization facilities in the global
registry of acute coronary events (the GRACE regis-
try), which reflects real-world clinical practice.
 
15
 
Second, as in FRISC II, most myocardial infarc-
tions in the early-invasive-strategy group in our
study were procedure-related.
 
16
 
 The higher inci-
dence of myocardial infarction in this group is
driven in large part by relatively small infarctions
related to percutaneous coronary intervention that
were detected with carefully timed and frequent
measurements of CK-MB levels. Moreover, we ap-
plied the Joint European Society of Cardiology–
discussion
 
Figure 1. Kaplan–Meier Estimates of the Cumulative Rate of the Composite 
Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitaliza-
tion for Anginal Symptoms within One Year.
 
The rate of a composite primary end point within one year was 22.7 percent in 
the group assigned to an early invasive strategy and 21.2 percent in the group 
assigned to a selectively invasive strategy (relative risk, 1.07; 95 percent confi-
dence interval, 0.87 to 1.33; P=0.33).
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American College of Cardiology definitions of spon-
taneous and percutaneous coronary intervention–
related myocardial infarction (peak CK-MB level,
greater than the upper limit of normal).
 
12
 
 Different
cutoff levels for infarctions related to percutane-
ous coronary intervention were used in FRISC II
(CK-MB level, >1.5 times the upper limit of nor-
mal), TACTICS–TIMI 18 (CK-MB level, ≥3 times
the upper limit of normal), and RITA-3 and Superi-
or Yield of the New Strategy of Enoxaparin, Re-
vascularization, and Glycoprotein IIb/IIIa Inhibi-
tors (SYNERGY) (CK-MB level, 2 times the upper
limit of normal). The incidence of myocardial in-
farction in the early-invasive-strategy group in our
study (15.0 percent at 1 year; median time to per-
cutaneous coronary intervention, 23 hours) was
similar to that in the recent SYNERGY trial (11.7
percent at 30 days; median time to percutaneous
coronary intervention, 23 hours), in which an early-
intervention strategy was used.
 
17
 
 
The prognostic implications of periprocedur-
al myocardial damage are controversial, but some
reports suggest that the prognosis of patients with
such injury should be regarded as similar to that
of patients with spontaneous necrosis.
 
16,18,19
 
 To
determine whether the increased incidence of pro-
 
* The tabulations of the composite primary end point include the first event — death, myocardial infarction, or rehospital-
ization — for each patient. The tabulations of component events include all such events (e.g., under the category 
“death,” all deaths are counted, including those that occurred after a hospitalization or a myocardial infarction). CI de-
notes confidence interval, ULN the upper limit of normal, FRISC II Fragmin and Fast Revascularization during Instability 
in Coronary Artery Disease II trial, and TACTICS–TIMI 18 the Treat Angina with Aggrastat and Determine Cost of Therapy 
with an Invasive Conservative Strategy–Thrombolysis in Myocardial Infarction 18 trial.
† The event rate within one year was determined with the use of the Kaplan–Meier curves.
‡ For the assessment of myocardial infarction, the level of the MB isoform of creatine kinase (CK-MB) was measured at 
6-hour intervals during the first period of 24 hours or more after admission, after each new clinical episode of recurrent 
ischemia, and after each percutaneous revascularization procedure.
§ The FRISC II definition of myocardial infarction is a CK-MB level above the upper limit of normal for spontaneous myo-
cardial infarction and more than 1.5 times the upper limit of normal for myocardial infarction related to percutaneous 
coronary intervention.
¶The TACTICS–TIMI 18 definition of myocardial infarction is a CK-MB level above the upper limit of normal for spontane-
ous myocardial infarction or more than three times the upper limit of normal for myocardial infarction related to percu-
 
taneous coronary intervention.
 
Table 3. Cumulative Rate of the Composite Primary End Point and Its Components within One Year after Randomization.*
Outcome
Early Invasive 
Strategy
(N=604)
Selectively Invasive 
Strategy
(N=596)
Relative Risk 
(95% CI) P Value
 
no. rate (%)
 
†
 
no. rate (%)
 
†
Death 15 2.5 15 2.5 0.99 (0.49–2.00) 0.97
Myocardial infarction‡ 90 15.0 59 10.0 1.50 (1.10–2.04) 0.005
Peak CK-MB ≥1 to <3¬ULN
 
 
 
43 7.2 27 4.6 1.57 (0.98–2.51) 0.05
Peak CK-MB ≥3 to <5¬ULN 15 2.5 7 1.2 2.09 (0.86–5.10) 0.09
Peak CK-MB ≥5 to <10¬ULN 14 2.3 13 2.2 1.06 (0.50–2.23) 0.86
Peak CK-MB ≥10¬ULN 11 1.8 6 1.0 1.79 (0.67–4.80) 0.23
No CK-MB, new Q waves 7 1.2 6 1.0 1.15 (0.39–3.37) 0.80
Spontaneous 22 3.7 27 4.6 0.80 (0.46–1.34) 0.45
Related to percutaneous coronary 
intervention or coronary-artery
bypass grafting
68 11.3 32 5.4 2.09 (1.39–3.14) 0.001
FRISC II definition§ 73 12.1 46 7.8 1.56 (1.10–2.22) 0.008
TACTICS–TIMI 18 definition¶ 51 8.5 35 5.9 1.43 (0.95–2.17) 0.07
Rehospitalization for anginal symptoms 44 7.4 64 10.9 0.68 (0.47–0.98) 0.04
Primary composite end point 137 22.7 126 21.2 1.07 (0.87–1.33) 0.33
FRISC II definition§ 122 20.2 115 19.3 1.05 (0.83–1.32) 0.52
TACTICS–TIMI 18 definition¶ 102 16.9 105 17.6 0.96 (0.75–1.23) 0.87
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cedure-related myocardial infarction in the early-
invasive-strategy group in our study eventually re-
sults in a worse prognosis will require long-term
follow-up. Regardless of the definition of myocar-
dial infarction in our study, we could not demon-
strate a significant difference in the incidence of
the composite primary end point between the two
treatment strategies.
Third, the incidence of myocardial infarction in
the group assigned to a selectively invasive strategy
was lower than expected. We incorporated recent
advances in background medical therapy, such as
the use of abciximab at the time of percutaneous
coronary intervention procedures, the early use of
clopidogrel, and intensive lipid-lowering therapy,
which have been shown to improve outcomes in
patients who have acute coronary syndromes with-
out ST-segment elevation.
 
10,20
 
 This may partially
explain the lower-than-expected event rate in the
group assigned to a selectively invasive strategy.
Finally, all procedures were performed in high-
volume centers with facilities for cardiac surgery
on site, resulting in a low overall mortality, includ-
ing a low mortality related to coronary-artery by-
pass grafting. In our view, advances in background
medical therapy in combination with better detec-
tion of myocardial infarctions with frequent, care-
fully timed measurements of CK-MB levels best ex-
plain the differences between our results and those
of previous trials.
The 2003 European Society of Cardiology
guidelines were published during the study enroll-
ment period. Physicians familiar with the guide-
lines would probably be inclined to favor perform-
ing angiography in most patients with an elevated
cardiac troponin T level. As a result, physicians par-
ticipating in our study might have enrolled lower-
risk patients than would otherwise have been in-
cluded. However, baseline characteristics suggest
that we studied a high-risk population, with more
than one third of the patients already taking aspi-
rin, more than half having ischemic changes as as-
 
Figure 2. Estimated Rates and Relative Risks of the Composite Primary End Point of Death, Nonfatal Myocardial 
Infarction, or Rehospitalization for Anginal Symptoms within One Year, According to Subgroup.
 
The frequency of the primary end points within one year after randomization was estimated from the Kaplan–Meier curves.
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sessed by electrocardiography, and all having an el-
evated cardiac troponin T level as confirmed with
core laboratory analysis.
We did not find the expected 25 percent reduc-
tion in the cumulative rate of the primary end point
with an early invasive strategy as compared with a
selectively invasive strategy. As a result, the confi-
dence interval around the relative risk of the com-
posite end point of death, myocardial infarction, or
rehospitalization for angina was 0.87 to 1.33, cor-
responding to a possible reduction in risk of 13 per-
cent (or an increase in risk of 33 percent) with an
early invasive strategy. However, the point estimate
for the relative risk (1.07) actually favors the selec-
tively invasive approach, and even the most sub-
stantial advantage of early invasive management
consistent with our data is much less than that esti-
mated in previous large trials.
Among patients with acute coronary syndromes
without ST-segment elevation who have an elevat-
ed cardiac troponin T level, we could not demon-
strate that an early invasive strategy was superior
to a selectively invasive strategy. These results were
obtained with the use of contemporary medical ther-
apy that included low-molecular-weight heparin,
glycoprotein IIb/IIIa inhibition at the time of per-
cutaneous procedures, clopidogrel, and intensive
lipid-lowering therapy.
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